[{"id":"b75ecd93-1120-4cfc-9f9a-b68e1481f48d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05588141","created_at":"2022-10-20T14:11:44.038Z","updated_at":"2025-02-25T12:29:09.098Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations","source_id_and_acronym":"NCT05588141","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zotiraciclib (TG02)"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 05/16/2023","start_date":" 05/16/2023","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/02/2029","study_completion_date":" 08/02/2029","last_update_posted":"2025-02-24"},{"id":"09433bad-7c17-41a7-b1ca-4ac19bbc5a86","acronym":"STEAM","url":"https://clinicaltrials.gov/study/NCT03224104","created_at":"2021-01-18T15:54:47.667Z","updated_at":"2024-07-02T16:36:09.663Z","phase":"Phase 1","brief_title":"Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma","source_id_and_acronym":"NCT03224104 - STEAM","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","biomarkers":" IDH1 • IDH2 • MCL1 • CDK9","pipe":" | ","alterations":" IDH1 R132H • IDH1 R132","tags":["IDH1 • IDH2 • MCL1 • CDK9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132H • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • zotiraciclib (TG02)"],"overall_status":"Completed","enrollment":" Enrollment 71","initiation":"Initiation: 06/12/2018","start_date":" 06/12/2018","primary_txt":" Primary completion: 05/05/2022","primary_completion_date":" 05/05/2022","study_txt":" Completion: 05/05/2022","study_completion_date":" 05/05/2022","last_update_posted":"2022-05-31"},{"id":"9c28c66f-c3b4-4633-96d1-74a5ed78d628","acronym":"","url":"https://clinicaltrials.gov/study/NCT02942264","created_at":"2021-01-18T14:26:49.487Z","updated_at":"2024-07-02T16:36:23.846Z","phase":"Phase 2","brief_title":"Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma","source_id_and_acronym":"NCT02942264","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • ATRX","pipe":"","alterations":" ","tags":["TP53 • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • zotiraciclib (TG02)"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 12/14/2016","start_date":" 12/14/2016","primary_txt":" Primary completion: 08/26/2020","primary_completion_date":" 08/26/2020","study_txt":" Completion: 08/26/2020","study_completion_date":" 08/26/2020","last_update_posted":"2021-09-28"}]